WILSON TROY EDWARD 4

What Happened
Troy Edward Wilson, a director of Puma Biotechnology (PBYI), received a grant of 27,000 restricted stock units (RSUs) on 2026-06-11 (reported at $0.00). The next day (2026-06-12) he sold 10,800 shares in an open-market transaction at a weighted-average price of $7.20 per share, generating approximately $77,748 in proceeds. The grant is an award (RSU) and the sale is an open-market disposal; sales are often routine or pre-planned rather than a direct bullish/bearish signal.

Key Details

• Grant: 27,000 RSUs on 2026-06-11 (reported value $0.00); vesting governed by footnote F1 (vests in full on earlier of one-year anniversary of grant or next annual meeting, subject to continued service).
• Sale: 10,800 shares sold on 2026-06-12; weighted-average price $7.20; total proceeds ≈ $77,748. Per footnote F3, actual sale prices ranged $6.98–$7.32 and the reporter can provide a breakdown on request.
• 10b5-1 plan: Footnote F2 indicates a 10b5-1 trading plan adoption date of 03-12-2025, indicating the sale may have been executed under a pre-established plan.
• Shares owned after transaction: Not specified in the provided filing.
• Filing date: Form 4 filed 2026-06-15 (covering 6/11–6/12 transactions); filing timeliness is not flagged in the provided data.

Context
RSUs are restricted stock awards that typically vest over time or upon certain events; they do not require an outlay to acquire (hence reported $0.00). A sale executed under a 10b5-1 plan usually means the trades were pre-scheduled and not necessarily a real-time expression of the insider’s view. For retail investors, purchases tend to be more informative than sales; this filing documents a routine award plus a partial, likely pre-planned, sale.